Aim of current study is to perform and investigate the renoprotective effect of nintedanib on diabetic nephropathy in albino wistar rat. Diabetic nephropathy was induced in overnight fasted rats by a single intraperitoneal injection of Streptozotocin (STZ) (45 mg/kg) prepared freshly in ice chilled 0.1 M citrate buffer (Ph-4.5) and after 15 minutes Nicotinamide (110 mg/kg)in in 0.9% normal saline was administered. The rat were divided into five grouping six animal in each group Each group underwent a different treatment protocol Treatment with nintedanib at 30 mg/kg and 50 mg/kg was evaluated using invivo studies such as physiological evaluation, serum and urine biochemical parameters like creatinine, albumin, BUN, uric acid and urine albumin level and histological studies of diabetic nephropathy induced rat's kidney. The present study demonstrated that the treatment of nintedanib exerts its renoprotective potential against the progression of diabetic nephropathy. The results showed significant improvements in renal function parameters and reduced histological changes when compared to the disease control group. Thereby, nintedanib at 50 mg/kg has demonstrated better effectiveness than nintedanib at 30 mg/kg. Our finding suggests that nintedanib holds potential as a novel therapeutic agent in the management of diabetic nephropathy by inhibiting TGF-L. vascular endothelial growth factors, and their signaling pathways in the progression of diabetic nephropathy. Further research is needed to elucidate its long-term safety and efficacy in clinical treatments.